| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 144, 329-336, Copyright © 1994 by American Society for Investigative Pathology
REGULAR ARTICLES |
JA Reed, NS McNutt and AP Albino
Department of Pathology, New York Hospital, Cornell Medical Center, New York.
Basic fibroblast growth factor (bFGF) is an angiogenic and mitogenic polypeptide produced by diverse cell types including cell lines derived from malignant melanomas but not from normal melanocytes. However, there is no consensus concerning in vivo expression of bFGF in melanocytic lesions due in part to the small numbers of cases studied to date. To evaluate further the possible differential expression of bFGF in melanocytic lesions, we examined 110 formalin-fixed, paraffin- embedded metastatic and primary invasive melanomas, melanomas in situ, nevi with architectural disorder and cytological atypia, and ordinary benign melanocyte nevi by nucleic acid in situ hybridization. All metastatic and primary invasive melanomas studied expressed bFGF mRNA, whereas melanomas in situ and benign melanocyte nevi were negative. Melanomas in situ with features of tumor regression and a majority of nevi with architectural disorder and cytological atypia also contained bFGF mrNA. The results suggest that in vivo bFGF expression is not requisite for malignant transformation per se, but appears to correlate more with invasion or fibroblastic reactions adjacent to the melanocyte lesions.
This article has been cited by other articles:
 |
|
 |
|
  J. M. Shields, N. E. Thomas, M. Cregger, A. J. Berger, M. Leslie, C. Torrice, H. Hao, S. Penland, J. Arbiser, G. Scott, et al. Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Signaling Shows a New Type of Melanoma Cancer Res., February 15, 2007; 67(4): 1502 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Stefanou, A. Batistatou, A. Zioga, E. Arkoumani, D. J. Papachristou, and N. J. Agnantis Immunohistochemical Expression of Vascular Endothelial Growth Factor (VEGF) and C-KIT in Cutaneous Melanocytic Lesions International Journal of Surgical Pathology, April 1, 2004; 12(2): 133 - 138. [Abstract] [PDF]
|
|
|
|
|
|
M. von Willebrand, E. Zacksenhaus, E. Cheng, P. Glazer, and R. Halaban The Tyrphostin AG1024 Accelerates the Degradation of Phosphorylated Forms of Retinoblastoma Protein (pRb) and Restores pRb Tumor Suppressive Function in Melanoma Cells Cancer Res., March 15, 2003; 63(6): 1420 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. A.-E. Hussein and G. S. Wood Molecular Aspects of Melanocytic Dysplastic Nevi J. Mol. Diagn., May 1, 2002; 4(2): 71 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S R Boyd, D S W Tan, L de Souza, M H Neale, N E Myatt, R A Alexander, M Robb, J L Hungerford, and I A Cree Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth Br. J. Ophthalmol., April 1, 2002; 86(4): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Auguste, D. B. Gürsel, S. Lemière, D. Reimers, P. Cuevas, F. Carceller, J. P. Di Santo, and A. Bikfalvi Inhibition of Fibroblast Growth Factor/Fibroblast Growth Factor Receptor Activity in Glioma Cells Impedes Tumor Growth by Both Angiogenesis-dependent and -independent Mechanisms Cancer Res., February 1, 2001; 61(4): 1717 - 1726. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold Increased Serum Concentration of Angiogenic Factors in Malignant Melanoma Patients Correlates With Tumor Progression and Survival J. Clin. Oncol., January 15, 2001; 19(2): 577 - 583. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
